Related Experiment Video
Updated: Aug 27, 2025
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis
Fabrizio Fabrizi1, Roberta Cerutti1, Vivek Dixit2
1Division of Nephrology, Dialysis and Transplantation IRCCS Ca Granda Foundation and Maggiore Polyclynic Hospital, Milano, Italy.
Insights
Sofosbuvir (SOF)-based direct-acting antiviral (DAA) regimens demonstrate high efficacy and safety in treating Hepatitis C virus (HCV) in patients with advanced chronic kidney disease (CKD). Careful monitoring of serum creatinine is recommended during SOF therapy for CKD patients.
Area of Science:
- Nephrology
- Hepatology
- Pharmacology
Background:
- Hepatitis C virus (HCV) infection is a significant cause of liver damage in patients with chronic kidney disease (CKD).
- Direct-acting antiviral (DAA) therapies have transformed HCV management, but their use in advanced CKD (stage 4-5) requires further evaluation.
- Sofosbuvir (SOF) is a key component of many DAA regimens, yet its appropriateness in patients with severe renal impairment remains uncertain.
Purpose of the Study:
- To systematically review and meta-analyze clinical studies evaluating the efficacy and safety of SOF-based DAA regimens in patients with stage 4-5 CKD.
- To assess the primary outcome of sustained virologic response (SVR12) as a measure of efficacy.
- To evaluate secondary outcomes including the frequency of serious adverse events (SAEs) and treatment drop-outs due to adverse events (AEs) as indicators of tolerability.
Main Methods:
- Systematic literature review and meta-analysis of clinical studies involving HCV-infected patients with stage 4-5 CKD treated with SOF-based DAA regimens.
- Utilized a random-effects model (DerSimonian and Laird) to pool data, incorporating heterogeneity and stratified analyses.
- Primary efficacy endpoint was SVR12; secondary endpoints included SAEs and AE-related drop-outs.
Main Results:
- Thirty studies (1537 patients) were analyzed, yielding a pooled SVR12 rate of 0.99 (95% CI, 0.97-1.0) and a pooled SAEs rate of 0.09 (95% CI, 0.05-0.13).
- Lower SVR12 rates were observed in studies with high baseline HCV RNA levels (0.87, 95% CI, 0.75-1.0).
- The pooled drop-out rate due to AEs was 0.02 (95% CI, -0.01-0.04). Common SAEs included anemia (38%) and reduced eGFR (19%). Higher SAE rates were noted with full-dose SOF and ribavirin-containing regimens. No consistent changes in eGFR were found post-therapy.
Conclusions:
- SOF-based DAA regimens are generally safe and effective for HCV treatment in patients with stage 4-5 CKD.
- Close monitoring of serum creatinine levels is crucial during SOF therapy in this patient population.
- Further randomized controlled trials are warranted to enhance understanding and confirm these findings.
Background:
Hepatitis C is an important agent of liver damage in patients with chronic kidney disease and the advent of DAAs has dramatically changed the management of HCV positive patients, including those with advanced CKD. Sofosbuvir is the backbone of many anti-HCV regimens based on DAAs but it remains unclear whether it is appropriate for HCV-infected patients with stage 4-5 CKD.
Study Aims And Design:
We performed a systematic review of the literature with a meta-analysis of clinical studies in order to evaluate the efficacy and safety of SOF-based DAA regimens in patients with stage 4-5 CKD. The primary outcome was sustained viral response (as a measure of efficacy); the secondary outcomes were the frequency of SAEs and drop-outs due to AEs (as measures of tolerability). The random-effects model of DerSimonian and Laird was adopted, with heterogeneity and stratified analyses.
Results:
Thirty clinical studies (n=1537 unique patients) were retrieved. The pooled SVR12 and SAEs rate was 0.99 (95% confidence intervals, 0.97; 1.0, I2=99.8%) and 0.09 (95% CI, 0.05; 0.13, I2=84.3%), respectively. The pooled SVR12 rate in studies with high HCV RNA levels at baseline was lower, 0.87 (95% CI, 0.75; 1.0, I2=73.3%) (P<0.001). The pooled drop-out rate due to AEs was 0.02 (95% CI, -0.01; 0.04, I2=16.1%). Common serious adverse events were anemia (n=26, 38%) and reduced eGFR (n=14, 19%). SAEs were more common in studies adopting full-dose sofosbuvir (pooled rate of SAEs 0.15, 95% CI, 0.06; 0.25; I2=80.1%) and in those based on ribavirin (0.15, 95% CI, 0.07; 0.23, I2=95.8%). Six studies (n=69 patients) reported eGFR levels at baseline/post- antiviral therapy; no consistent changes were found.
Conclusions:
SOF-based regimens appear safe and effective in patients with stage 4-5 CKD. Serum creatinine should be carefully monitored during therapy with SOF in patients with CKD. Randomized controlled studies in order to expand our knowledge on this point are under way.
More Related Videos
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
08:58Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Related Concept Videos
01:18Chronic Kidney Disease IV: Nursing Management
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:28Chronic Kidney Disease III: Interprofessional Care